Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for ATYR1940 in adults with facioscapulohumeral muscular dystrophy reports safety, tolerability, pharmacokinetics, and biological activit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• ATYR1940

Snippet

Sponsor: aTyr Pharma, Inc. | Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-08-11